Abiopharma

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

XORTX Announces USD $925,000 Private Placement

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Balchem Corporation to Present at the CJS Annual New Ideas Summer Conference on July 10, 2025

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Pfizer Inc. - Pfizer Announces Positive Topline Phase 3 Results forHYMPAVZI™ in Hemophilia A or B with Inhibitors

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Edgewise Therapeutics - Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by Chinas NMPA